In addition to the utility of diagnosis and prognosis for MPN patients, our platform can contribute to precise quantification of JAK2V617Fsomatic mutation of CH of indeterminate potential in the general population, which typically exhibits a low mutation allele burden.26The recent study from Danish General Suburban population screening research, found that a JAK2V617Fpopulation prevalence of 3.1% with a mean allele burden of 2.1%. This evidence concerns the gene C4B and myeloproliferative neoplasm.